IASO Group proudly participates in the Rebrain Greece MOL NEW YORK event, organized in collaboration with the Ministry of Labour & Social Security and the General Directorate of Labour Relations, Health, Safety and Work Inclusion. The event will take place on December 7th, 2025, at the Marriott Marquis Times Square from 10:00 to 18:00.
Representing the Greek private healthcare sector, IASO Group with both an in-person presence and an interactive booth, travels to the USA to present to the Greek community of New York its know-how, mode of operation, as well as its vision for the future of healthcare in Greece. Attendees will have the opportunity to learn more about:
- Innovation
- Technology
- People
More specifically, we will present:
- the Group’s work and growth strategy,
- our modern infrastructure and cutting-edge technological solutions,
- and the professional opportunities available to Greek healthcare professionals – doctors, nursing, and midwifery personnel – who wish to or are considering the possibility of returning to Greece.
Our participation aims to create new partnerships and form connections with the Greek medical community abroad, paving the way for a modern, and innovative healthcare landscape in Greece. We look forward to meeting you, so as to build the future of healthcare together within one of the largest Healthcare Groups and the biggest Private Hospital in Greece.
We explore prospects. We create opportunities. We invest in human capital.
Learn more and submit your application: bit.ly/IASOGroup_RebrainGreece
IASO: Neonatal BabyGen – Neonatal Genomic Screening
IASO, the largest Maternity & Gynecology Clinic in Europe, in collaboration with Neoscreen, introduces the Neonatal BabyGen genomic screening, an innovative examination that paves the way for the future of preventive medicine.
Neonatal BabyGen is a screening that enables the early detection of serious genetic, metabolic, and rare disorders through the analysis of a newborn’s DNA, from the very first days of their life. The screening focuses on a targeted analysis of 500 – 600 high-significance genes that are associated with hereditary conditions, metabolic disorders, rare but serious syndromes and conditions that can be prevented or treated. In this way, parents and treating physicians gain valuable insight that allows for early prevention, monitoring and, where necessary, therapeutic intervention, even before symptoms appear.
The process is simple, painless, and completely safe: only a few drops of blood are needed, which are analyzed using Next Generation Sequencing (NGS) technology. The results are delivered to parents within 15–20 business days and are accompanied by clinical genetic counseling.
Neoscreen is a specialized laboratory in Greece, having the technological capability for comprehensive genomic screening, with 20 years of experience in neonatal clinical screening and over 10 years of expertise in genome analysis.
With Neonatal BabyGen, IASO and Neoscreen offer parents the opportunity to give their children an invaluable gift: knowledge about the future of their health.